Cathepsin D, a Lysosomal Protease, Regulates ABCA1-mediated Lipid Efflux*

To identify genes involved in the regulation of plasma high density lipoprotein (HDL) cholesterol (HDL-C) levels, patients with low HDL-C and age- and sex-matched controls (normal HDL-C) were extensively characterized. Comparative transcriptome analysis was carried out in cholesterol-loaded monocyte-derived macrophages from low HDL subjects segregated into groups with or without cholesterol efflux defects or ABCA1 mutations. Clusters of differentially regulated genes were evident in the low HDL groups as compared with controls. Of particular note, expression of cathepsin D (CTSD), a lysosomal proteinase, was reduced by ∼50% in monocyte-derived macrophages of low HDL-C subjects, most significantly those with cholesterol efflux defects but without mutations in ABCA1 (p < 0.01). These results were verified by reverse transcription-PCR and replicated in a second cohort. We show here that blocking the activity or expression of CTSD, by pepstatin or CTSD small interfering RNA, respectively, reduced ABCA1 expression and protein abundance in both macrophages and CHO cells and apolipoprotein A-I-mediated lipid efflux by more than 70%. Conversely, expression of CTSD increased both ABCA1 mRNA expression and cellular ABCA1 protein. Consistent with its role in the proteolytic processing of prosaposin, inactivation of CTSD function resulted in the accumulation of glycosphingo-lipid and free cholesterol in late endosomes/lysosomes, a phenotype similar to NPC1 deficiency. Inhibition of CTSD also caused retention of ABCA1 in lysosomal compartments, reducing its trafficking to the plasma membrane. These studies demonstrate a novel and potentially important role for CTSD in intracellular cholesterol trafficking and ABCA1-mediated efflux. Therefore, decreased CTSD expression may contribute to low plasma HDL-C levels.

[1]  V. Laurent-Matha,et al.  Cathepsin D: newly discovered functions of a long-standing aspartic protease in cancer and apoptosis. , 2006, Cancer letters.

[2]  K. Blennow,et al.  The Cathepsin D rs17571 polymorphism: effects on CSF tau concentrations in Alzheimer disease , 2006, Human mutation.

[3]  A. Lehesjoki,et al.  Cathepsin D deficiency underlies congenital human neuronal ceroid-lipofuscinosis. , 2006, Brain : a journal of neurology.

[4]  S. Sonnino,et al.  Saposin B binds and transfers phospholipids Published, JLR Papers in Press, February 6, 2006. , 2006, Journal of Lipid Research.

[5]  H. McBride,et al.  The Lipoprotein Receptor-related Protein-1 (LRP) Adapter Protein GULP Mediates Trafficking of the LRP Ligand Prosaposin, Leading to Sphingolipid and Free Cholesterol Accumulation in Late Endosomes and Impaired Efflux* , 2006, Journal of Biological Chemistry.

[6]  Y. Dobashi,et al.  Overexpression in colorectal carcinoma of two lysosomal enzymes, CLN2 and CLN1, involved in neuronal ceroid lipofuscinosis , 2006, Cancer.

[7]  G. Johnson,et al.  A mutation in the cathepsin D gene (CTSD) in American Bulldogs with neuronal ceroid lipofuscinosis. , 2006, Molecular genetics and metabolism.

[8]  C. Eng,et al.  Genetic variation of PLTP modulates lipoprotein profiles in hypoalphalipoproteinemia Published, JLR Papers in Press, December 30, 2005. , 2006, Journal of Lipid Research.

[9]  P. Tontonoz,et al.  Liver X receptors as integrators of metabolic and inflammatory signaling. , 2006, The Journal of clinical investigation.

[10]  J. Villadangos,et al.  Destructive potential of the aspartyl protease cathepsin D in MHC class II‐restricted antigen processing , 2005, European journal of immunology.

[11]  V. Vetvicka,et al.  Dual role of cathepsin D: ligand and protease. , 2005, Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia.

[12]  I. Gelissen,et al.  Glycosphingolipid Accumulation Inhibits Cholesterol Efflux via the ABCA1/Apolipoprotein A-I Pathway , 2005, Journal of Biological Chemistry.

[13]  M. Elleder,et al.  Prosaposin deficiency -- a rarely diagnosed, rapidly progressing, neonatal neurovisceral lipid storage disease. Report of a further patient. , 2005, Neuropediatrics.

[14]  H. Grosch,et al.  Purified recombinant human prosaposin forms oligomers that bind procathepsin D and affect its autoactivation. , 2004, The Biochemical journal.

[15]  Jonathan C. Cohen,et al.  Multiple Rare Alleles Contribute to Low Plasma Levels of HDL Cholesterol , 2004, Science.

[16]  R. Desnick,et al.  Lipid abnormalities in children with types A and B Niemann Pick disease. , 2004, The Journal of pediatrics.

[17]  R. Dwek,et al.  Accumulation of Glycosphingolipids in Niemann-Pick C Disease Disrupts Endosomal Transport* , 2004, Journal of Biological Chemistry.

[18]  H. Chapman,et al.  Cathepsins as transcriptional activators? , 2004, Developmental cell.

[19]  J. Genest,et al.  Apolipoprotein A-I Activates Cellular cAMP Signaling through the ABCA1 Transporter* , 2004, Journal of Biological Chemistry.

[20]  C. Peters,et al.  Cathepsin L is involved in cathepsin D processing and regulation of apoptosis in A549 human lung epithelial cells , 2004, Biological chemistry.

[21]  S. Witting,et al.  Ceramide Enhances Cholesterol Efflux to Apolipoprotein A-I by Increasing the Cell Surface Presence of ATP-binding Cassette Transporter A1* , 2003, Journal of Biological Chemistry.

[22]  V. Puri,et al.  Sphingolipid Storage Induces Accumulation of Intracellular Cholesterol by Stimulating SREBP-1 Cleavage* , 2003, Journal of Biological Chemistry.

[23]  R. Pagano Endocytic trafficking of glycosphingolipids in sphingolipid storage diseases. , 2003, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[24]  K. Sandhoff,et al.  Biosynthesis and degradation of mammalian glycosphingolipids. , 2003, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[25]  R. Dwek,et al.  Glucosylceramide modulates membrane traffic along the endocytic pathway Published, JLR Papers in Press, August 16, 2002. DOI 10.1194/jlr.M200232-JLR200 , 2002, Journal of Lipid Research.

[26]  R. Dwek,et al.  Modulation of THP-1 macrophage and cholesterol-loaded foam cell apolipoprotein E levels by glycosphingolipids. , 2002, Biochemical and biophysical research communications.

[27]  C. Isidoro,et al.  Endosomal-Lysosomal Proteolysis Mediates Death Signalling by TNFα, Not by Etoposide, in L929 Fibrosarcoma Cells: Evidence for an Active Role of Cathepsin D , 2002, Biological chemistry.

[28]  A. Tall,et al.  Acid Sphingomyelinase-deficient Macrophages Have Defective Cholesterol Trafficking and Efflux* , 2001, The Journal of Biological Chemistry.

[29]  A. Remaley,et al.  Cellular Localization and Trafficking of the Human ABCA1 Transporter* 210 , 2001, The Journal of Biological Chemistry.

[30]  J. Brady,et al.  Analysis of Glomerulosclerosis and Atherosclerosis in Lecithin Cholesterol Acyltransferase-deficient Mice* , 2001, The Journal of Biological Chemistry.

[31]  M. Elleder,et al.  A novel mutation in the coding region of the prosaposin gene leads to a complete deficiency of prosaposin and saposins, and is associated with a complex sphingolipidosis dominated by lactosylceramide accumulation. , 2001, Human molecular genetics.

[32]  R. Kinscherf,et al.  Ceramide induces aSMase expression: implications for oxLDL-induced apoptosis , 2001 .

[33]  J. Genest,et al.  Decreased cellular cholesterol efflux is a common cause of familial hypoalphalipoproteinemia: role of the ABCA1 gene mutations. , 2000, Atherosclerosis.

[34]  A. Tall,et al.  Phospholipid transfer protein gene knock-out mice have low high density lipoprotein levels, due to hypercatabolism, and accumulate apoA-IV-rich lamellar lipoproteins. , 2000, Journal of lipid research.

[35]  P. Denéfle,et al.  Human ATP-binding cassette transporter 1 (ABC1): genomic organization and identification of the genetic defect in the original Tangier disease kindred. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[36]  C. Sensen,et al.  Mutations in the ABC 1 gene in familial HDL deficiency with defective cholesterol efflux , 1999, The Lancet.

[37]  A. Vaughan,et al.  The Tangier disease gene product ABC1 controls the cellular apolipoprotein-mediated lipid removal pathway. , 1999, The Journal of clinical investigation.

[38]  V. Puri,et al.  Cholesterol modulates membrane traffic along the endocytic pathway in sphingolipid-storage diseases , 1999, Nature Cell Biology.

[39]  W. Schneider-Brachert,et al.  Cathepsin D targeted by acid sphingomyelinase‐derived ceramide , 1999, The EMBO journal.

[40]  A. von Eckardstein,et al.  Apolipoprotein A-I(R151C)Paris is defective in activation of lecithin:cholesterol acyltransferase but not in initial lipid binding, formation of reconstituted lipoproteins, or promotion of cholesterol efflux , 1999, Journal of Molecular Medicine.

[41]  T. Langmann,et al.  The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease , 1999, Nature Genetics.

[42]  J. Piette,et al.  Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1 , 1999, Nature Genetics.

[43]  C. Sensen,et al.  Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency , 1999, Nature Genetics.

[44]  T. Langmann,et al.  Molecular cloning of the human ATP-binding cassette transporter 1 (hABC1): evidence for sterol-dependent regulation in macrophages. , 1999, Biochemical and biophysical research communications.

[45]  A. Tall,et al.  Targeted mutation of plasma phospholipid transfer protein gene markedly reduces high-density lipoprotein levels. , 1999, The Journal of clinical investigation.

[46]  A. von Eckardstein,et al.  Multiple dysfunctions of two apolipoprotein A-I variants, apoA-I(R160L)Oslo and apoA-I(P165R), that are associated with hypoalphalipoproteinemia in heterozygous carriers. , 1999, Journal of lipid research.

[47]  G. Luc,et al.  Severe atherosclerosis and hypoalphalipoproteinemia in the staggerer mouse, a mutant of the nuclear receptor RORalpha. , 1998, Circulation.

[48]  J. Ordovás,et al.  β-glucocerebrosidase gene locus as a link for Gaucher's disease and familial hypo-α-lipoproteinaemia , 1998, The Lancet.

[49]  M. Tremblay,et al.  Familial HDL deficiency characterized by hypercatabolism of mature apoA-I but not proapoA-I. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[50]  J. Virtamo,et al.  Molecular Genetic Study of Finns With Hypoalphalipoproteinemia and Hyperalphalipoproteinemia A Novel Gly230Arg Mutation (LCATFin) of Lecithin:Cholesterol Acyltransferase (LCAT) Accounts for 5% of Cases With Very Low Serum HDL Cholesterol Levels , 1998 .

[51]  A. von Eckardstein,et al.  A natural apolipoprotein A-I variant, apoA-I (L141R)Pisa, interferes with the formation of alpha-high density lipoproteins (HDL) but not with the formation of pre beta 1-HDL and influences efflux of cholesterol into plasma. , 1997, Journal of lipid research.

[52]  G. Luc,et al.  Fish-eye disease: structural and in vivo metabolic abnormalities of high-density lipoproteins. , 1997, Metabolism: clinical and experimental.

[53]  N. Maeda,et al.  Targeted disruption of the mouse sphingolipid activator protein gene: a complex phenotype, including severe leukodystrophy and wide-spread storage of multiple sphingolipids. , 1996, Human molecular genetics.

[54]  K. Sandhoff,et al.  Topology of glycosphingolipid degradation. , 1996, Trends in cell biology.

[55]  M. Sheikh,et al.  Retinoid regulation of human cathepsin D gene expression , 1996, The Journal of Steroid Biochemistry and Molecular Biology.

[56]  B. Troen,et al.  Regulation of cathepsin D gene expression in HL-60 cells by retinoic acid and calcitriol. , 1995, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[57]  F. May,et al.  The human cathepsin D-encoding gene is transcribed from an estrogen-regulated and a constitutive start point. , 1993, Gene.

[58]  Y. Kishimoto,et al.  Saposins: structure, function, distribution, and molecular genetics. , 1992, Journal of lipid research.

[59]  K. Sandhoff,et al.  Activator proteins and topology of lysosomal sphingolipid catabolism. , 1992, Biochimica et biophysica acta.

[60]  H. Grosch,et al.  Molecular organization of the human cathepsin D gene. , 1991, DNA and cell biology.

[61]  Y. Kishimoto,et al.  Saposin proteins: structure, function, and role in human lysosomal storage disorders , 1991, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[62]  G. Conner Isolation of procathepsin D from mature cathepsin D by pepstatin affinity chromatography. Autocatalytic proteolysis of the zymogen form of the enzyme. , 1989, The Biochemical journal.

[63]  R. Fagerstrom,et al.  Reduced plasma concentrations of total, low density lipoprotein and high density lipoprotein cholesterol in patients with Gaucher type I disease , 1984, Clinical genetics.

[64]  R. Dean Direct evidence of importance of lysosomes in degradation of intracellular proteins , 1975, Nature.

[65]  W. J. Dyer,et al.  A rapid method of total lipid extraction and purification. , 1959, Canadian journal of biochemistry and physiology.

[66]  R. Andrzejak,et al.  Cathepsin D expression in human colorectal cancer: relationship with tumour type and tissue differentiation grade. , 2005, Journal of experimental therapeutics & oncology.

[67]  J. Genest,et al.  Cellular cholesterol transport and efflux in fibroblasts are abnormal in subjects with familial HDL deficiency. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[68]  H. Rochefort,et al.  Cathepsin D gene is controlled by a mixed promoter, and estrogens stimulate only TATA-dependent transcription in breast cancer cells. , 1993, Proceedings of the National Academy of Sciences of the United States of America.